Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,075 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The inhibitor of differentiation-1 (Id1) enables lung cancer liver colonization through activation of an EMT program in tumor cells and establishment of the pre-metastatic niche.
Castañón E, Soltermann A, López I, Román M, Ecay M, Collantes M, Redrado M, Baraibar I, López-Picazo JM, Rolfo C, Vidal-Vanaclocha F, Raez L, Weder W, Calvo A, Gil-Bazo I. Castañón E, et al. Among authors: lopez picazo jm, lopez i. Cancer Lett. 2017 Aug 28;402:43-51. doi: 10.1016/j.canlet.2017.05.012. Epub 2017 May 24. Cancer Lett. 2017. PMID: 28549790
Safety and efficacy of maintenance therapy with a nonspecific cytochrome P17 inhibitor (CYP17i) after response/stabilization to docetaxel in metastatic castration-resistant prostate cancer.
Gil-Bazo I, Arévalo E, Castillo A, Zudaire ME, Carranza OE, Fusco JP, Castañón E, Collado-Gómez V, López I, Gil-Aldea I. Gil-Bazo I, et al. Among authors: lopez i. Clin Genitourin Cancer. 2013 Jun;11(2):78-84. doi: 10.1016/j.clgc.2012.11.003. Epub 2012 Dec 21. Clin Genitourin Cancer. 2013. PMID: 23260990
Differential tumor expression of inhibitor of differentiation-1 in prostate cancer patients with extreme clinical phenotypes and prognostic implications.
Ponz-Sarvisé M, Castañón E, Panizo-Santos A, Redrado M, López I, Rosell D, Gil-Aldea I, Calvo A, Nguewa PA, Gil-Bazo I. Ponz-Sarvisé M, et al. Among authors: lopez i. Clin Genitourin Cancer. 2014 Apr;12(2):87-93. doi: 10.1016/j.clgc.2013.08.007. Epub 2013 Oct 12. Clin Genitourin Cancer. 2014. PMID: 24129125
Thymidylate synthase polymorphisms in genomic DNA as clinical outcome predictors in a European population of advanced non-small cell lung cancer patients receiving pemetrexed.
Arévalo E, Castañón E, López I, Salgado J, Collado V, Santisteban M, Rodríguez-Ruiz M, Martín P, Zubiri L, Patiño-García A, Rolfo C, Gil-Bazo I. Arévalo E, et al. Among authors: lopez i. J Transl Med. 2014 Apr 14;12:98. doi: 10.1186/1479-5876-12-98. J Transl Med. 2014. PMID: 24726028 Free PMC article.
Impact of epidermal growth factor receptor (EGFR) activating mutations and their targeted treatment in the prognosis of stage IV non-small cell lung cancer (NSCLC) patients harboring liver metastasis.
Castañón E, Rolfo C, Viñal D, López I, Fusco JP, Santisteban M, Martin P, Zubiri L, Echeveste JI, Gil-Bazo I. Castañón E, et al. Among authors: lopez i. J Transl Med. 2015 Aug 7;13:257. doi: 10.1186/s12967-015-0622-x. J Transl Med. 2015. PMID: 26248464 Free PMC article.
Inhibitor of Differentiation-1 Sustains Mutant KRAS-Driven Progression, Maintenance, and Metastasis of Lung Adenocarcinoma via Regulation of a FOSL1 Network.
Román M, López I, Guruceaga E, Baraibar I, Ecay M, Collantes M, Nadal E, Vallejo A, Cadenas S, Miguel ME, Jang JH, Martin-Uriz PS, Castro-Labrador L, Vilas-Zornoza A, Lara-Astiaso D, Ponz-Sarvise M, Rolfo C, Santos ES, Raez LE, Taverna S, Behrens C, Weder W, Wistuba II, Vicent S, Gil-Bazo I. Román M, et al. Among authors: lopez i. Cancer Res. 2019 Feb 1;79(3):625-638. doi: 10.1158/0008-5472.CAN-18-1479. Epub 2018 Dec 18. Cancer Res. 2019. PMID: 30563891
1,075 results